HLA-DRaα1-mMOG-35-55 treatment of experimental autoimmune encephalomyelitis reduces CNS inflammation, enhances M2 macrophage frequency, and promotes neuroprotection

Gil Benedek, Roberto Meza-Romero, Kelley Jordan, Lucy Keenlyside, Halina Offner, Arthur Vandenbark

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: DRaα1-mouse(m)MOG-35-55, a novel construct developed in our laboratory as a simpler and potentially less immunogenic alternative to two-domain class II constructs, was shown previously to target the MIF/CD74 pathway and to reverse clinical and histological signs of experimental autoimmune encephalomyelitis (EAE) in DR*1501-Tg mice in a manner similar to the parent DR2β1-containing construct. Methods: In order to determine whether DRaα1-mMOG-35-55 could treat EAE in major histocompatibility complex (MHC)-mismatched mice and to evaluate the treatment effect on central nervous system (CNS) inflammation, C57BL/6 mice were treated with DRaα1-mMOG-35-55. In addition, gene expression profile was analyzed in spinal cords of EAE DR*1501-Tg mice that were treated with DRaα1-mMOG-35-55. Results: We here demonstrate that DRaα1-mMOG-35-55 could effectively treat EAE in MHC-mismatched C57BL/6 mice by reducing CNS inflammation, potentially mediated in part through an increased frequency of M2 monocytes in the spinal cord. Microarray analysis of spinal cord tissue from DRaα1-mMOG-35-55-treated vs. vehicle control mice with EAE revealed decreased expression of a large number of pro-inflammatory genes including CD74, NLRP3, and IL-1β and increased expression of genes involved in myelin repair (MBP) and neuroregeneration (HUWE1). Conclusion: These findings indicate that the DRaα1-mMOG-35-55 construct retains therapeutic, anti-inflammatory, and neuroprotective activities during treatment of EAE across MHC disparate barriers.

Original languageEnglish (US)
Article number123
JournalJournal of Neuroinflammation
Volume12
Issue number1
DOIs
StatePublished - Jun 24 2015

Fingerprint

Autoimmune Experimental Encephalomyelitis
Central Nervous System
Macrophages
Inflammation
Major Histocompatibility Complex
Spinal Cord
Inbred C57BL Mouse
Microarray Analysis
Myelin Sheath
Interleukin-1
Transcriptome
Neuroprotection
Monocytes
Anti-Inflammatory Agents
Gene Expression
Genes

Keywords

  • DRaα1-mMOG-35-55 therapy
  • Experimental autoimmune encephalomyelitis (EAE)
  • M2 macrophages
  • Multiple sclerosis (MS)
  • Neuroprotection

ASJC Scopus subject areas

  • Neuroscience(all)
  • Cellular and Molecular Neuroscience
  • Neurology
  • Immunology

Cite this

HLA-DRaα1-mMOG-35-55 treatment of experimental autoimmune encephalomyelitis reduces CNS inflammation, enhances M2 macrophage frequency, and promotes neuroprotection. / Benedek, Gil; Meza-Romero, Roberto; Jordan, Kelley; Keenlyside, Lucy; Offner, Halina; Vandenbark, Arthur.

In: Journal of Neuroinflammation, Vol. 12, No. 1, 123, 24.06.2015.

Research output: Contribution to journalArticle

@article{cbc1ecebba15413286b54909f52f796c,
title = "HLA-DRaα1-mMOG-35-55 treatment of experimental autoimmune encephalomyelitis reduces CNS inflammation, enhances M2 macrophage frequency, and promotes neuroprotection",
abstract = "Background: DRaα1-mouse(m)MOG-35-55, a novel construct developed in our laboratory as a simpler and potentially less immunogenic alternative to two-domain class II constructs, was shown previously to target the MIF/CD74 pathway and to reverse clinical and histological signs of experimental autoimmune encephalomyelitis (EAE) in DR*1501-Tg mice in a manner similar to the parent DR2β1-containing construct. Methods: In order to determine whether DRaα1-mMOG-35-55 could treat EAE in major histocompatibility complex (MHC)-mismatched mice and to evaluate the treatment effect on central nervous system (CNS) inflammation, C57BL/6 mice were treated with DRaα1-mMOG-35-55. In addition, gene expression profile was analyzed in spinal cords of EAE DR*1501-Tg mice that were treated with DRaα1-mMOG-35-55. Results: We here demonstrate that DRaα1-mMOG-35-55 could effectively treat EAE in MHC-mismatched C57BL/6 mice by reducing CNS inflammation, potentially mediated in part through an increased frequency of M2 monocytes in the spinal cord. Microarray analysis of spinal cord tissue from DRaα1-mMOG-35-55-treated vs. vehicle control mice with EAE revealed decreased expression of a large number of pro-inflammatory genes including CD74, NLRP3, and IL-1β and increased expression of genes involved in myelin repair (MBP) and neuroregeneration (HUWE1). Conclusion: These findings indicate that the DRaα1-mMOG-35-55 construct retains therapeutic, anti-inflammatory, and neuroprotective activities during treatment of EAE across MHC disparate barriers.",
keywords = "DRaα1-mMOG-35-55 therapy, Experimental autoimmune encephalomyelitis (EAE), M2 macrophages, Multiple sclerosis (MS), Neuroprotection",
author = "Gil Benedek and Roberto Meza-Romero and Kelley Jordan and Lucy Keenlyside and Halina Offner and Arthur Vandenbark",
year = "2015",
month = "6",
day = "24",
doi = "10.1186/s12974-015-0342-4",
language = "English (US)",
volume = "12",
journal = "Journal of Neuroinflammation",
issn = "1742-2094",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - HLA-DRaα1-mMOG-35-55 treatment of experimental autoimmune encephalomyelitis reduces CNS inflammation, enhances M2 macrophage frequency, and promotes neuroprotection

AU - Benedek, Gil

AU - Meza-Romero, Roberto

AU - Jordan, Kelley

AU - Keenlyside, Lucy

AU - Offner, Halina

AU - Vandenbark, Arthur

PY - 2015/6/24

Y1 - 2015/6/24

N2 - Background: DRaα1-mouse(m)MOG-35-55, a novel construct developed in our laboratory as a simpler and potentially less immunogenic alternative to two-domain class II constructs, was shown previously to target the MIF/CD74 pathway and to reverse clinical and histological signs of experimental autoimmune encephalomyelitis (EAE) in DR*1501-Tg mice in a manner similar to the parent DR2β1-containing construct. Methods: In order to determine whether DRaα1-mMOG-35-55 could treat EAE in major histocompatibility complex (MHC)-mismatched mice and to evaluate the treatment effect on central nervous system (CNS) inflammation, C57BL/6 mice were treated with DRaα1-mMOG-35-55. In addition, gene expression profile was analyzed in spinal cords of EAE DR*1501-Tg mice that were treated with DRaα1-mMOG-35-55. Results: We here demonstrate that DRaα1-mMOG-35-55 could effectively treat EAE in MHC-mismatched C57BL/6 mice by reducing CNS inflammation, potentially mediated in part through an increased frequency of M2 monocytes in the spinal cord. Microarray analysis of spinal cord tissue from DRaα1-mMOG-35-55-treated vs. vehicle control mice with EAE revealed decreased expression of a large number of pro-inflammatory genes including CD74, NLRP3, and IL-1β and increased expression of genes involved in myelin repair (MBP) and neuroregeneration (HUWE1). Conclusion: These findings indicate that the DRaα1-mMOG-35-55 construct retains therapeutic, anti-inflammatory, and neuroprotective activities during treatment of EAE across MHC disparate barriers.

AB - Background: DRaα1-mouse(m)MOG-35-55, a novel construct developed in our laboratory as a simpler and potentially less immunogenic alternative to two-domain class II constructs, was shown previously to target the MIF/CD74 pathway and to reverse clinical and histological signs of experimental autoimmune encephalomyelitis (EAE) in DR*1501-Tg mice in a manner similar to the parent DR2β1-containing construct. Methods: In order to determine whether DRaα1-mMOG-35-55 could treat EAE in major histocompatibility complex (MHC)-mismatched mice and to evaluate the treatment effect on central nervous system (CNS) inflammation, C57BL/6 mice were treated with DRaα1-mMOG-35-55. In addition, gene expression profile was analyzed in spinal cords of EAE DR*1501-Tg mice that were treated with DRaα1-mMOG-35-55. Results: We here demonstrate that DRaα1-mMOG-35-55 could effectively treat EAE in MHC-mismatched C57BL/6 mice by reducing CNS inflammation, potentially mediated in part through an increased frequency of M2 monocytes in the spinal cord. Microarray analysis of spinal cord tissue from DRaα1-mMOG-35-55-treated vs. vehicle control mice with EAE revealed decreased expression of a large number of pro-inflammatory genes including CD74, NLRP3, and IL-1β and increased expression of genes involved in myelin repair (MBP) and neuroregeneration (HUWE1). Conclusion: These findings indicate that the DRaα1-mMOG-35-55 construct retains therapeutic, anti-inflammatory, and neuroprotective activities during treatment of EAE across MHC disparate barriers.

KW - DRaα1-mMOG-35-55 therapy

KW - Experimental autoimmune encephalomyelitis (EAE)

KW - M2 macrophages

KW - Multiple sclerosis (MS)

KW - Neuroprotection

UR - http://www.scopus.com/inward/record.url?scp=84933050077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933050077&partnerID=8YFLogxK

U2 - 10.1186/s12974-015-0342-4

DO - 10.1186/s12974-015-0342-4

M3 - Article

VL - 12

JO - Journal of Neuroinflammation

JF - Journal of Neuroinflammation

SN - 1742-2094

IS - 1

M1 - 123

ER -